Navigation Links
Data Conversion Laboratory Supports Newest SPL Requirements For Life Sciences Industry
Date:8/4/2009

FRESH MEADOWS, N.Y., Aug. 4 /PRNewswire/ -- Data Conversion Laboratory, Inc. (DCL), providing conversion services and software to publishers, information aggregators, industry, government, libraries and documentation developers, continues to be in the forefront supporting the life sciences community in complying with the FDA's SPL (Structured Product Labeling) initiative.

SPL is an XML standard used by the FDA community to facilitate communicating drug labeling data reliably among various medical groups. Since 2005, the FDA CDER division has mandated that all human prescription drugs be provided in SPL. Beginning in June, 2009 the FDA has required SPL filings for biologics, veterinary medicines and over-the-counter (OTC) products. Medical devices are expected to require SPL filing in 2010. Additionally, as a result of the Food and Drug Administration Amendments Act of 2007 mandating electronic submissions, SPL is now required for establishment registration, NDC labeler code requests and drug listing regulatory requirements.

As one of the world's leading providers of data conversion services, DCL has been well-positioned to understand the structure and usage of this new standard, and to assist affected organizations in implementing and utilizing SPL in a timely and efficient manner. DCL supports the full range of SPL filings, is up to date on all technical requirements and has implemented sophisticated multi-level quality assurance checks to validate SPL files prior to submission. To date, DCL has successfully completed more than 2,000 filings.

Mark Gross, DCL president, expanded on DCL's involvement with these regulations: "As a long-time member of the SPL Working Group helping to establish these standards, we were very comfortable with SPL from the beginning. As standards continue to evolve, our 28 years of industry experience and our ongoing interaction with the group enable us to provide rapid turnaround in support of our clients' labeling conversions with guaranteed conformance to FDA and EMEA standards."

About Data Conversion Laboratory, Inc.

Founded in 1981, DCL converts and organizes content to create electronic documents, populate databases and publish on the web, sustaining long-term strategic relationships with clients preparing for tomorrow's technology. DCL operates with facilities on four continents, providing support services for high-volume data-entry and data-processing using its real-time web-accessible process control software. DCL's services help refine conversion strategy, identify document redundancy, extract metadata and transform legacy and future documents to meet our clients' real needs - today and in the future. DCL converts from any format to any format, and has processed more than a quarter billion pages.

    Contact:
    Don Bridges, SPL Product Manager
    505-275-2223
    dbridges@dclab.com
    www.dclab.com


'/>"/>
SOURCE Data Conversion Laboratory, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Blood Test Shows Statistically Significant Association With Alzheimers Disease (AD), May Predict Conversion of Mild Cognitive Impairment to AD
2. Leading University Hospital Completes System-Wide Conversion to Masimo SET(R) Pulse Oximetry
3. Patent Issued for UNIVAL(R) D3(TM) Data Conversion System
4. Covidien Canada Streamlines Integration and Processing of Fax-based Orders With GHX G-Fax(TM) Fax Conversion Service
5. Kentucky Medical Services Foundation Completes Successful Charge Capture Technology Conversion
6. Triple-S Management Corporation Announces Conversion of Class A Shares and Commencement of Class B Stock Repurchase Program
7. NJHA: Public Deserves Full Disclosure of Horizon Conversion Plan
8. Bioniche Allows Conversion of Portion of Revolving Credit Facility
9. Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
10. MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million
11. Smart Balance Announces Conversion of Convertible Preferred Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an ... an educational webinar, they will present the line of epMotion automated liquid handling ... easy you can automate everyday pipetting tasks. , Ideal for scientists and lab ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: